“Edison’s accessible and high-quality research gives us the opportunity to communicate an independent perspective of Tyman to a wide variety of potential stakeholders.”
Associated equity: Vivesto
Vivesto — 3 videos in collection
Oasmia Pharmaceutical is a Swedish speciality pharma company focusing on its proprietary XR-17 technology platform to develop novel formulations of well-established cytostatic oncology treatments for human and animal health. Key assets include Apealea (partnered with Elevar), docetaxel micellar and Cantrixil.
• Tell us about Oasmia and provide a high-level overview of its ongoing transformation.
• What can be expected from the imminent European launch of Apealea and what are your commercialisation plans?
• Please describe your ‘string of pearls’ strategy and how you are using it to build a diversified oncology portfolio.
• Please provide an update on the development of Cantrixil and the planned next steps, as well as on your other clinical asset, docetaxel micellar?
• Which milestones should investors focus on in the coming year?
Get access to the very latest content matched to your personal investment style.
